Next Article in Journal
Abdominal Desmoid: Course, Severe Outcomes, and Unique Genetic Background in a Large Local Series
Previous Article in Journal
Anastasis: Return Journey from Cell Death
Previous Article in Special Issue
Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits

Oncolytic Virus Immunotherapy

Laboratory of Oncolytic Virus Immuno-Therapeutics, Luxembourg Institute of Health, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg
German Cancer Research Centre, Laboratory of Oncolytic Virus Immuno-Therapeutics, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Institute of Cancer Research, London SW3 6JB, UK
Author to whom correspondence should be addressed.
Cancers 2021, 13(15), 3672;
Received: 12 May 2021 / Accepted: 7 July 2021 / Published: 22 July 2021
(This article belongs to the Special Issue Oncolytic Virus Immunotherapy)
Note: In lieu of an abstract, this is an excerpt from the first page.

Oncolytic viruses (OVs) were originally developed as direct cytotoxic agents but have been increasingly recognised as a form of immunotherapy [...] View Full-Text
MDPI and ACS Style

Marchini, A.; Ilkow, C.S.; Melcher, A. Oncolytic Virus Immunotherapy. Cancers 2021, 13, 3672.

AMA Style

Marchini A, Ilkow CS, Melcher A. Oncolytic Virus Immunotherapy. Cancers. 2021; 13(15):3672.

Chicago/Turabian Style

Marchini, Antonio, Carolina S. Ilkow, and Alan Melcher. 2021. "Oncolytic Virus Immunotherapy" Cancers 13, no. 15: 3672.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop